Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 8-K (Current Report)
Date of Report: July 17, 2025
Event: Submission of Matters to a Vote of Security Holders at the Annual Meeting held via live webcast.
Key Financial Metrics
This filing is a corporate governance report regarding stockholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
No material financial changes are reported in this document. The filing details the outcome of two stockholder proposals:
- Proposal 1 (Election of Director): Mark A. Goldberg was elected as a Class II director to serve until the 2028 annual meeting.
- Proposal 2 (Ratification of Auditor): Stockholders ratified the selection of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is limited to the reporting of voting statistics.
Important Facts for Investors to Verify
- Voting Participation: Approximately 59.73% of outstanding shares (10,989,589 shares) were represented at the meeting, establishing a quorum.
- Director Election Results: Mark A. Goldberg received 6,979,703 votes "For," 222,974 "Withheld," and 3,786,912 "Broker Non-Votes."
- Auditor Ratification Results: The ratification of EisnerAmper LLP received 10,929,292 votes "For," 16,730 "Against," and 43,567 "Abstain."
- Emerging Growth Company Status: The registrant is identified as an emerging growth company.